SHINE Creates Therapeutics Division, Will Attend 2019 European Association of Nuclear Medicine Conference
SHINE Medical Technologies, LLC today announced the creation of a new division of the company — SHINE Therapeutics. The establishment of the division enhances the company’s ability to focus on filling critical future needs in the rapidly growing therapeutic isotope market, while continuing to leverage its radioisotope production expertise.
The company’s Therapeutics division will initially focus on the development and commercialization of lutetium‑177, or Lu‑177, a therapeutic isotope that is combined with a disease-specific targeting molecule to treat cancer. Targeting molecules deliver Lu‑177 atoms to cancer sites throughout the body, where they directly irradiate cancer cells.
The first Lu‑177-based targeted radiotherapy (for neuroendocrine tumors) reached the market in 2018. Many high-potential targeted molecules for the treatment of a range of other cancers with Lu-177 are currently under investigation. SHINE is also evaluating additional medical isotopes with therapeutic properties for future development.
Katrina Pitas, a 10-year veteran of SHINE who served most recently as the company’s vice president of business development, has been appointed vice president and general manager of SHINE Therapeutics.
“Targeted radiotherapy has the potential to fundamentally change the way cancer patients are treated,” Ms. Pitas said. “But a robust, reliable supply of therapeutic isotopes will be crucial as both the discipline and associated market continue to grow. Our Lu‑177 development program is well underway, and we look forward to bringing high-purity Lu‑177 to market.”
In May, the company entered an agreement with the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB Prague) that provides SHINE with a global, exclusive license to a novel separation technology that it will use to separate lutetium from enriched ytterbium targets. The technology will enable SHINE to produce non-carrier-added, high-specific-activity Lu‑177.
“We are excited to bring our core competencies and technology to serve the rapidly emerging therapeutic market,” said Greg Piefer, SHINE’s founder and CEO. “This market is particularly exciting, as it offers very promising therapies for patients who before now had difficult or impossible to treat late stage cancers. The focus of our new division is to ensure cancer patients have a reliable supply chain of isotopes as new drugs are approved.”
SHINE is continuing its efforts to bring molybdenum-99, or Mo‑99, to a global market experiencing shortages that directly affect patient care. Construction of the company’s first-of-its-kind isotope production facility in Janesville, Wis., where it will produce Mo‑99 using the company’s patented technology, is underway and progressing well.
European Association of Nuclear Medicine Annual Congress
SHINE will be exhibiting at the European Association of Nuclear Medicine (EANM) Annual Congress in Barcelona, Spain. The exhibit hall will be open Oct. 13-15. You can find SHINE at booth no. 23 near the center entrance to the exhibit hall.
About SHINE Medical Technologies LLC
Founded in 2010, SHINE is a development-stage company working to become a manufacturer of radioisotopes for nuclear medicine. The SHINE system uses a patented, proprietary manufacturing process that offers major advantages over existing and proposed production technologies. It does not require a nuclear reactor, uses less electricity, generates less waste and is compatible with the nation’s existing supply chain for Mo-99. In 2014, SHINE announced the execution of Mo-99 supply agreements with GE Healthcare and Lantheus Medical Imaging. In 2015, with the help of Argonne National Laboratory, GE Healthcare demonstrated that SHINE Mo-99 can act as a drop-in replacement for reactor-based Mo-99. In 2016, SHINE received regulatory approval from the Nuclear Regulatory Commission to construct its production facility. The company began construction of the facility in the spring of 2019. Learn more at https://shinemed.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191011005509/en/
Contact information
Rod Hise
Director, Marketing & Corporate Communications
pr@shinemed.com
608-530-5659
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Nakiki SE: Nakiki SE Evaluates Corporate Bond Offering for Strategic Bitcoin Investment27.8.2025 19:51:00 EEST | Press release
Nakiki SE is currently evaluating the issuance of a corporate bond with a target volume in the mid–single-digit million-euro range. As part of a pre-market sounding process, the Management Board is assessing interest from professional investors. The proceeds of the issuance are intended primarily for the acquisition of Bitcoin. Language: English Company: Nakiki SE Hanauer Landstr. 204 60314 Frankfurt on the Main Germany E-mail: info@nakikifinance.com Internet: https://nakikifinance.com/ ISIN: DE000WNDL300, DE000WNDL318 WKN: WNDL30, WNDL31 Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange View source version on businesswire.com: https://www.businesswire.com/news/home/20250827593566/en/
Boomi Named a Leader and Secures Top Score in Strategy Category in Latest iPaaS Report by Independent Research Firm27.8.2025 18:30:00 EEST | Press release
Boomi™, the leader in AI-driven automation, today announced it has been named a Leader in The Forrester Wave™: Integration Platform As A Service, Q3 2025. The report evaluated the 10 most significant iPaaS vendors, and Boomi achieved the highest score in thestrategy category among all evaluated providers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250826324359/en/ Boomi Named a Leader and Secures Top Score in Strategy Category in Latest iPaaS Report by Independent Research Firm The report states that Boomi has reoriented with an “intense focus on AI and APIs,” “receives strong feedback from its partners,” and maintains “clear investment priorities.” Reference customers were impressed by the company’s level of investment in the product and its vision for the future, and look forward to seeing Boomi deliver on its AI roadmap. “We’re honored to be named a Leader in the Forrester Wave — and especially proud to receive the to
Altasciences and Evidence Matters Announce Strategic Collaboration to Advance AI-Enhanced Text Engineering for Regulatory Writing in Life Sciences27.8.2025 17:00:00 EEST | Press release
Altasciences, a fully integrated CRO/CDMO offering comprehensive early-phase drug development solutions, is pleased to announce a strategic collaboration with Evidence Matters, a pioneer in clinical trial data science and document engineering. This partnership combines Altasciences' real-world drug development expertise with Evidence Matters' innovative, patent-pending Text Engineering technology—a breakthrough that delivers near-deterministic accuracy in regulatory writing by reducing variability and improving the quality, consistency, and speed of documentation. Evidence Matters’ RegulatoryFlow platform (“RegFlow”) and specialized services unify clinical data and documents, simplify workflows, and accelerate the work of key life sciences professionals, from medical writers to regulatory specialists. “We are excited to work alongside Evidence Matters to co-develop technology that directly enhances the quality and efficiency of regulatory writing,” said Nicole Maciolek, Vice President,
Andersen Consulting Adds Collaborating Firm Skribble27.8.2025 16:30:00 EEST | Press release
Andersen Consulting expands its strategy and business transformation capabilities through a Collaboration Agreement with Skribble, a digital and brand consultancy supporting innovation and operational transformation for companies in Southeast Asia. Established in 2020, Skribble offers a wide range of services, including brand and communications strategy, digital marketing, custom technology development, change management, and platform solutions. The firm supports organizations in real estate, consumer goods, banking, and government by aligning strategy with execution to deliver integrated brand, performance, and technology solutions. With a focus on process optimization and a full creative and technical skillset, Skribble helps clients drive transformation and growth. “At Skribble, we pride ourselves on translating creative energy into strategic outcomes,” said Chan Leong, CEO of Skribble. “We approach each client with precision and passion, applying deep market insight, sharp executio
Veridas Named a Visionary in the 2025 Gartner® Magic Quadrant™ for Identity Verification27.8.2025 15:34:00 EEST | Press release
Veridas, a global identity company, has been recognized as a Visionary in the 2025 Gartner® Magic Quadrant™ for Identity Verification, reinforcing its position among the top global IDV vendors. Founded in 2017 and operating globally, Veridas enters the report as one of the fastest-growing companies in the market. Gartner defines Visionaries as vendors that understand where the market is going or have a vision for changing market rules. This positioning validates Veridas’ long-term strategy and highlights its leadership in innovation, ethical design, and user-centric digital identity. At the core of Veridas’ approach is its 100% proprietary technology stack, covering facial biometrics, voice authentication, document verification, age validation, physical access control, and its ID Wallet. By developing all core technologies in-house, Veridas ensures full control over security, performance, and compliance, enabling end-to-end protection against fraud, higher user conversion rates, and gr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom